Literature DB >> 8214044

Pressor doses of angiotensin II increase insulin-mediated glucose uptake in normotensive men.

R R Townsend1, D J DiPette.   

Abstract

The effect of pressor doses of angiotensin II infused intravenously on insulin-mediated glucose uptake was determined in normotensive men. A 3-h hyperinsulinemic euglycemic clamp was employed in 14 normotensive subjects to determine insulin-mediated glucose uptake with or without an infusion of angiotensin II (approximately 15 ng.kg-1.min-1), which increased blood pressure by 20/15 mmHg (systolic/diastolic). Addition of angiotensin II increased whole body glucose uptake by 15% (9.2 +/- 0.5 vs. 10.8 +/- 0.8 mg.kg-1 x min-1; P = 0.011), and glucose oxidation (determined by indirect calorimetry) by 25% (4.0 +/- 0.3 vs. 4.9 +/- 0.4 mg.kg-1 x min-1; P < 0.05) over insulin alone. There was no significant increase in hepatic glucose output during angiotensin II infusion (2.2 +/- 0.1 vs. 2.4 +/- 0.1 mg.kg-1 x min-1; P = NS). We conclude that angiotensin II in pressor doses increases insulin-mediated glucose disposal and oxidation. The mechanism for this may involve a redirection of blood flow into skeletal muscle during angiotensin II infusion or a direct biochemical action of angiotensin II. Although performed in lean normotensive subjects, these results cast doubt on a significant role for angiotensin II in the insulin resistance associated with essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8214044     DOI: 10.1152/ajpendo.1993.265.3.E362

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  11 in total

Review 1.  The link between the renin-angiotensin-aldosterone system and renal injury in obesity and the metabolic syndrome.

Authors:  Tina Thethi; Masumi Kamiyama; Hiroyuki Kobori
Journal:  Curr Hypertens Rep       Date:  2012-04       Impact factor: 5.369

2.  ACE genotype may have an effect on single versus multiple set preferences in strength training.

Authors:  Muzaffer Colakoglu; F Sirri Cam; Bulent Kayitken; Firat Cetinoz; Sule Colakoglu; Mustafa Turkmen; Metin Sayin
Journal:  Eur J Appl Physiol       Date:  2005-07-08       Impact factor: 3.078

Review 3.  Metabolic actions of angiotensin II and insulin: a microvascular endothelial balancing act.

Authors:  Ranganath Muniyappa; Sahzene Yavuz
Journal:  Mol Cell Endocrinol       Date:  2012-06-07       Impact factor: 4.102

4.  The effects of the renin-angiotensin-aldosterone system gene polymorphisms on insulin resistance in hypertensive families.

Authors:  Chin-Fu Hsiao; Wayne W H Sheu; Yi-Jen Hung; Ming-Wei Lin; David Curb; Koustubh Ranadex; Thomas Quertermous; Yue-Ming Chen; Ida Yi-Der Chen; Kwan-Dun Wu
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2012-03-14       Impact factor: 1.636

Review 5.  The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome.

Authors:  Kelly Putnam; Robin Shoemaker; Frederique Yiannikouris; Lisa A Cassis
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-01-06       Impact factor: 4.733

Review 6.  Angiotensin and insulin resistance: conspiracy theory.

Authors:  Raymond R Townsend
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

Review 7.  The renin angiotensin aldosterone system and insulin resistance in humans.

Authors:  Patricia C Underwood; Gail K Adler
Journal:  Curr Hypertens Rep       Date:  2013-02       Impact factor: 5.369

8.  Differential predictors of insulin resistance in nondiabetic salt-resistant and salt-sensitive subjects.

Authors:  Cheryl L Laffer; Fernando Elijovich
Journal:  Hypertension       Date:  2013-01-02       Impact factor: 10.190

9.  Angiotensin II induces tyrosine phosphorylation of insulin receptor substrate 1 and its association with phosphatidylinositol 3-kinase in rat heart.

Authors:  M J Saad; L A Velloso; C R Carvalho
Journal:  Biochem J       Date:  1995-09-15       Impact factor: 3.857

10.  Secondary metabolites of Cynodon dactylon as an antagonist to angiotensin II type1 receptor: Novel in silico drug targeting approach for diabetic retinopathy.

Authors:  R K Jananie; V Priya; K Vijayalakshmi
Journal:  J Pharmacol Pharmacother       Date:  2012-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.